Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 8Sarcoma 4Genitourinary 4Gastrointestinal 2CNS 2Thoracic 1NET 1Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Lung Neoplasms 3647Carcinoma, Non-Small-Cell Lung 3587Small Cell Lung Carcinoma 578Breast Neoplasms 420Neoplasms 299Adenocarcinoma of Lung 249Colorectal Neoplasms 222Melanoma 201Mesothelioma, Malignant 183Pancreatic Neoplasms 179Brain Neoplasms 179Prostatic Neoplasms 178Head and Neck Neoplasms 173Neoplasm Metastasis 167Ovarian Neoplasms 153Esophageal Neoplasms 152Mesothelioma 145Colonic Neoplasms 140Stomach Neoplasms 139NSCLC 115Pleural Effusion, Malignant 114Carcinoma, Renal Cell 109Urinary Bladder Neoplasms 106Disease 96Sarcoma 85Uterine Cervical Neoplasms 82Thymoma 79Liver Neoplasms 77Motor Activity 75Squamous Cell Carcinoma of Head and Neck 72

Interventions

Radiotherapy 1Paclitaxel 1Erlotinib Hydrochloride 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma, Clear Cell × Thoracic × Clear all
NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 11 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡